← Eichor
Study identifier: NCT06182774 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

Condition: Multiple Myeloma  ·  Sponsor: Canadian Cancer Trials Group

PhasePhase 3
Planned participants570
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Currently, daratumumab or isatuximab are given continuously (non-stop), along side lenalidomide, and dexamethasone as part of multiple myeloma treatment. are given continuously (non-stop). Recent observations suggest that stopping daratumumab or isatuximb after about a year and a half of treatment may work just as well as giving them continuously with lenalidomide and dexamethasone. Sometimes, bortezomib is also given. This study is being done to answer the question: is less daratumumab or isatuximab treatment as good as more?

This description comes directly from the study's public registry record.

Talk to the study team

Annette Hay  ·  613-533-6430  ·  ahay@ctg.queensu.ca

Always discuss trial participation with your own doctor first.

Locations (28)

Cross Cancer InstituteEdmonton, Alberta, CanadaRecruiting
BCCA - KelownaKelowna, British Columbia, CanadaRecruiting
BCCA - VancouverVancouver, British Columbia, CanadaRecruiting
CancerCare ManitobaWinnipeg, Manitoba, CanadaRecruiting
The Moncton HospitalMoncton, New Brunswick, CanadaRecruiting
Regional Health Authority B, Zone 2Saint John, New Brunswick, CanadaRecruiting
Dr. H. Bliss Murphy Cancer CentreSt. John's, Newfoundland and Labrador, CanadaRecruiting
Royal Victoria Regional Health CentreBarrie, Ontario, CanadaRecruiting
William Osler Health SystemBrampton, Ontario, CanadaRecruiting
Juravinski Cancer Centre at Hamilton Health SciencesHamilton, Ontario, CanadaRecruiting
Kingston Health Sciences CentreKingston, Ontario, CanadaRecruiting
Waterloo Regional Health Network (WRHN)Kitchener, Ontario, CanadaRecruiting

+ 16 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06182774